製品番号: HY-N0264

Ligustrazine

(別名: Chuanxiongzine; Tetramethylpyrazine; 2,3,5,6-テトラメチルピラジン)

11 Cited Publications

カスタマーレビュー

Based on 11 publication(s) in Google Scholar

Ligustrazine (Chuanxiongzine), an alkylpyrazine isolated from Ligusticum chuanxiong Hort. (Chuan Xiong), is present in french fries, bread, cooked meats, tea, cocoa, coffee, beer, spirits, peanuts, filberts, dairy products and soy products as fragrance and flavouring ingredienexhibits. Ligustrazine also has potential nootropic and anti-inflammatory activities in rats.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.99%
CAS 番号: 1124-11-4
分子式: C₈H₁₂N₂
分子量:136.19

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Ligustrazine 構造式

CAS 番号: 1124-11-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 臨床実験
化学情報
Publications (11)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Ligustrazine (Chuanxiongzine), an alkylpyrazine isolated from Ligusticum chuanxiong Hort. (Chuan Xiong)^[1], is present in french fries, bread, cooked meats, tea, cocoa, coffee, beer, spirits, peanuts, filberts, dairy products and soy products as fragrance and flavouring ingredienexhibits. Ligustrazine also has potential nootropic and anti-inflammatory activities in rats^[2]^[3].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>20 μM Compound: Lig	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37499289]
A549	IC₅₀	>200 μM Compound: 1	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 26891099]
A549	IC₅₀	>200 μM Compound: 1	Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry	[PMID: 26891099]
A549	IC₅₀	15.22 μM Compound: 2	Antiproliferative activity against human A549 cells after 72 hrs in presence of piperlongumine by MTT assay Antiproliferative activity against human A549 cells after 72 hrs in presence of piperlongumine by MTT assay	[PMID: 29424539]
A549	IC₅₀	36.46 μM Compound: TMP	Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
A549	IC₅₀	6.42 μM Compound: Lig	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay	[PMID: 37499289]
A549/CDDP	IC₅₀	>200 μM Compound: 1	Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay	[PMID: 26891099]
A549/CDDP	IC₅₀	>200 μM Compound: 1	Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry	[PMID: 26891099]
Bel-7402	IC₅₀	>20 μM Compound: Ligustrazine	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 29432947]
EA.hy 926	EC₅₀	83.4 μM Compound: Ligustrazine, TMP	Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay	10.1039/C4MD00022F
ECV-304	EC₅₀	0.6 mM Compound: TMP, Ligustrazine	Cytoprotective activity in H2O2-induced human ECV304 cells assessed as proliferation rate incubated for 24 hrs prior to H2O2-challenge measured after 12 hrs by MTT assay Cytoprotective activity in H2O2-induced human ECV304 cells assessed as proliferation rate incubated for 24 hrs prior to H2O2-challenge measured after 12 hrs by MTT assay	10.1039/C3MD20352B
ECV-304	EC₅₀	0.6 mM Compound: TMP, tetramethyl pyrazine	Protection against H2O2-induced toxicity in human ECV304 cells assessed as proliferation rate pretreated for 24 hrs before H2O2 challenge measured after 12 hrs by MTT assay Protection against H2O2-induced toxicity in human ECV304 cells assessed as proliferation rate pretreated for 24 hrs before H2O2 challenge measured after 12 hrs by MTT assay	[PMID: 21993151]
ECV-304	EC₅₀	154.35 μM Compound: Lig, Ligustrazine	Protection against hydrogen peroxide-induced cell damage in human ECV304 cells treated 30 mins before hydrogen peroxide challenge measured after 6 hrs Protection against hydrogen peroxide-induced cell damage in human ECV304 cells treated 30 mins before hydrogen peroxide challenge measured after 6 hrs	[PMID: 19329327]
ECV-304	EC₅₀	452 μM Compound: ligustrazine	Protection of hydrogen peroxide-induced damage in ECV304 cells Protection of hydrogen peroxide-induced damage in ECV304 cells	[PMID: 17383884]
ECV-304	EC₅₀	549 μM Compound: Ligustrazine	Protection against H2O2-induced damage in human ECV304 cells preincubated for 24 hrs followed by H2O2 addition and measured after 12 hrs by MTT assay Protection against H2O2-induced damage in human ECV304 cells preincubated for 24 hrs followed by H2O2 addition and measured after 12 hrs by MTT assay	[PMID: 29432947]
HBMEC-2	EC₅₀	15.18 μM Compound: TMP	Neuroprotective activity against H2O2-induced cell damage in human HBMEC2 cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay Neuroprotective activity against H2O2-induced cell damage in human HBMEC2 cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay	[PMID: 31541868]
HCT-116	IC₅₀	8.17 μM Compound: 2	Antiproliferative activity against human HCT116 cells after 72 hrs in presence of piperlongumine by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs in presence of piperlongumine by MTT assay	[PMID: 29424539]
HeLa	IC₅₀	>20 μM Compound: Ligustrazine	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29432947]
HepG2	IC₅₀	>20 μM Compound: Ligustrazine	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 29432947]
HepG2	IC₅₀	38.25 μM Compound: TMP	Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
HT-29	IC₅₀	>20 μM Compound: Ligustrazine	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 29432947]
HUVEC	EC₅₀	600 μM Compound: Ligustrazine	Protection against H2O2-induced damage in HUVEC Protection against H2O2-induced damage in HUVEC	[PMID: 29432947]
HUVEC	EC₅₀	788 μM Compound: Ligustrazine	Protection against H2O2-induced damage in HUVEC preincubated for 0.5 hrs followed by H2O2 addition and measured after 12 hrs Protection against H2O2-induced damage in HUVEC preincubated for 0.5 hrs followed by H2O2 addition and measured after 12 hrs	[PMID: 29432947]
K562	IC₅₀	5.09 μM Compound: 2	Antiproliferative activity against human K562 cells after 72 hrs in presence of piperlongumine by MTT assay Antiproliferative activity against human K562 cells after 72 hrs in presence of piperlongumine by MTT assay	[PMID: 29424539]
MCF7	IC₅₀	>20 μM Compound: Ligustrazine	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 29432947]
MCF7	IC₅₀	29.85 μM Compound: TMP	Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
MDA-MB-231	IC₅₀	20.44 μM Compound: TMP	Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
MDA-MB-231	IC₅₀	4.86 μM Compound: Lig	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay	[PMID: 37499289]
MG-63	IC₅₀	10.3 μg/mL Compound: 46	Cytotoxicity against human MG-63 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MG-63 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37300915]
NCI-H1975	IC₅₀	5.61 μM Compound: Lig	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay	[PMID: 37499289]
PC-12	EC₅₀	60 μM Compound: Ligustrazine	Neuroprotection against CoCl2-induced toxicity in rat PC12 cells Neuroprotection against CoCl2-induced toxicity in rat PC12 cells	[PMID: 29432947]
PC-12	EC₅₀	64.46 μM Compound: Ligustrazine	Neuroprotection against CoCl2-induced toxicity in rat PC12 cells preincubated for 36 hrs followed by CoCl2 addition measured after 12 hrs by MTT assay Neuroprotection against CoCl2-induced toxicity in rat PC12 cells preincubated for 36 hrs followed by CoCl2 addition measured after 12 hrs by MTT assay	[PMID: 29432947]
Platelet	IC₅₀	265.3 μM Compound: Ligustrazine, TMP	Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins at 37 degC by aggregometry Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins at 37 degC by aggregometry	10.1039/C4MD00022F
SAOS-2	IC₅₀	24.7 μg/mL Compound: 46	Cytotoxicity against human SAOS-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SAOS-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37300915]
SH-SY5Y	EC₅₀	17.59 μM Compound: TMP	Neuroprotective activity against H2O2-induced cell damage in human SH-SY5Y cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay Neuroprotective activity against H2O2-induced cell damage in human SH-SY5Y cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay	[PMID: 31541868]
SK-HEP1	IC₅₀	9.67 μM Compound: Lig	Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay	[PMID: 37499289]
U2OS	IC₅₀	54.7 μg/mL Compound: 46	Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37300915]
U-87MG ATCC	IC₅₀	16.15 μM Compound: 2	Antiproliferative activity against human U87MG cells after 72 hrs in presence of piperlongumine by MTT assay Antiproliferative activity against human U87MG cells after 72 hrs in presence of piperlongumine by MTT assay	[PMID: 29424539]

体外実験

Ligustrazine has been extensively used in China for cardiovascular and cerebrovascular diseases for about 40 years. Because of its effectiveness in multisystem, especially in cardiovascular. Ligustrazine also has been used in various diseases, such as coronary heart disease, diabetes, cancers, and liver injury^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 1124-11-4
性状 Solid
分子量 136.19
分子式 C₈H₁₂N₂
Color White to off-white
SMILES

CC1=C(C)N=C(C)C(C)=N1
別名

Chuanxiongzine; Tetramethylpyrazine; 2,3,5,6-テトラメチルピラジン
Structure Classification
- Others
Initial Source
- Plants
- Umbelliferae
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (11)

All Histological Imaging/StainingIn Vivo ImagingELISAIn Vivo Efficacy StudyCell Imaging/StainingCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Antioxidants (Basel)

Dopamine D2 Receptor Activation Blocks GluA2/ROS Positive Feedback Loop to Alienate Chronic-Migraine-Associated Pain Sensitization. [Abstract]

2024 Jun 14;13(6):725. PMID: 38929165
Biochem Pharmacol

Tetramethylpyrazine ameliorates sepsis-induced liver injury via inhibiting ferroptosis. [Abstract]

2025 Jul 26:241:117193. PMID: 40721008

Ligustrazine purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Jul 26:241:117193. [Abstract]

Ligustrazine (TMP, 25-100 mg/kg; i.p.; once daily for 7 days) can ameliorate liver injury in septic mice: Pathological changes in liver tissues of mice in each group, yellow arrows: hepatic cords; black arrows: hepatocytes. H&E staining results showed that in the Sham group, the liver tissues were structurally intact and morphologically normal, with no cell necrosis; in the CLP group, hepatocytes were swollen and necrotic, and hepatic cords were disorganized, accompanied by extensive inflammatory cell infiltration; compared with the CLP group, liver tissue damage in the CLP + XBJ, CLP + TMP L (25 mg/kg), CLP + TMP M (50 mg/kg), and CLP + TMP H (100 mg/kg) groups was significantly improved, hepatic cord structure was restored, and inflammatory cell infiltration was reduced, with the most significant improvement in the CLP + XBJ and CLP + TMP H groups.

Ligustrazine purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Jul 26:241:117193. [Abstract]

Effects of Ligustrazine (TMP, 25-100 mg/kg; i.p.; once daily for 7 days) on serum levels of IL-6, TNF-α, and IL-10 in septic mice.
Eur J Pharmacol

Tetramethylpyrazine ameliorates 5-fluorouracil-Induced cardiotoxicity by inhibiting PANoptosis and suppressing the p38 MAPK/JNK/ERK signaling pathway. [Abstract]

2025 Sep 17:178180. PMID: 40973012

Ligustrazine purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 17:178180. [Abstract]

Representative M-mode echocardiograms. Echocardiographic analysis revealed that Ligustrazine (TMP, 60 mg/kg; i.p.; once daily for 10 days) treatment significantly improved 5-FU (20 mg/kg; i.p.; once daily for 10 days)-induced cardiac dysfunction in BALB/c mice.

Ligustrazine purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 17:178180. [Abstract]

Morphological analysis showed that Ligustrazine (TMP, 60 mg/kg; i.p.; once daily for 10 days) attenuated 5-FU (20 mg/kg; i.p.; once daily for 10 days)-induced reductions in heart size, and significantly restored HW/TL ratio in BALB/c mice.

Ligustrazine purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 17:178180. [Abstract]

Representative images of cardiac tissue with HE staining. Images were taken at 40 × and 400 ×. HE staining revealed that Ligustrazine (TMP, 60 mg/kg; i.p.; once daily for 10 days) significantly ameliorated 5-FU (20 mg/kg; i.p.; once daily for 10 days)-induced cardiomyocyte disarray, inflammatory cell infiltration, and histological disruptions in BALB/c mice.

Ligustrazine purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 17:178180. [Abstract]

Representative micrographs were taken at 100 × magnification with a scale bar of 100 μm. Ligustrazine (TMP, 12.5 μM; 48 h) treatment significantly reversed the reduction in cell density induced by 5-FU (10 μM; 48 h).

Ligustrazine purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 17:178180. [Abstract]

Ligustrazine (TMP) (6.25-100 μM; 48 h) alone exhibited no cytotoxic effects on H9C2 cells. Co-treatment with TMP (12.5–50 μM; 48 h) significantly reversed the suppression of cell viability induced by 10 μM 5-FU.
Cell Signal

Tetramethylpyrazine protects against myocardial ischemia/reperfusion injury via regulating Myl2-mediated NLRP3 signaling pathway inhibition. [Abstract]

2025 Nov:135:112045. PMID: 40754120
Regen Ther

Therapeutic effects of Tetramethylpyrazine on Cartilage in Rat Model of Post-traumatic Osteoarthritis. [Abstract]

2026 Mar 7:32:101098. PMID: 41852452
Exp Cell Res

Tetramethylpyrazine inhibits neutrophil extracellular traps formation and alleviates hepatic ischemia/reperfusion injury in rat liver transplantation. [Abstract]

2021 Sep 1;406(1):112719. PMID: 34273405
Chem Biol Drug Des

Tetramethylpyrazine Targets HDAC6-Mediated PINK1 Degradation to Alleviate Chronic Intermittent Hypoxia-Induced Injury in Human Bronchial Epithelial Cells (16HBE). [Abstract]

2026 Jan;107(1):e70236. PMID: 41549472
Clin Exp Pharmacol Physiol

Ligustrazine and liguzinediol protect against doxorubicin-induced cardiomyocytes injury by inhibiting mitochondrial apoptosis and autophagy. [Abstract]

2023 Nov;50(11):867-877. PMID: 37574718
Vascular

Ligustrazine activate the PPAR-γ pathway and play a protective role in vascular calcification. [Abstract]

2022 Dec;30(6):1224-1231. PMID: 34670463
Research Square Print

November 8th, 2022
Research Square Print

October 11th, 2022.

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (367.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

7.3427 mL

36.7134 mL

73.4268 mL

5 mM

1.4685 mL

7.3427 mL

14.6854 mL

10 mM

0.7343 mL

3.6713 mL

7.3427 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (18.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (18.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (18.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/0.5% Tween-80 in Saline water

Solubility: 15.92 mg/mL (116.90 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (277 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Zhao Y, et al. Mechanisms and Clinical Application of Tetramethylpyrazine (an Interesting Natural Compound Isolated from Ligusticum Wallichii): Current Status and Perspective. Oxid Med Cell Longev. 2016;2016:2124638. [Content Brief]

[2]. Wu W, et al. Tetramethylpyrazine protects against scopolamine-induced memory impairments in rats by reversing the cAMP/PKA/CREB pathway. Behav Brain Res. 2013 Sep 15;253:212-6. [Content Brief]

[3]. Kao TK, et al. Tetramethylpyrazine reduces cellular inflammatory response following permanent focal cerebral ischemia in rats. Exp Neurol. 2013 Sep;247:188-201. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	7.3427 mL	36.7134 mL	73.4268 mL	183.5671 mL
	5 mM	1.4685 mL	7.3427 mL	14.6854 mL	36.7134 mL
	10 mM	0.7343 mL	3.6713 mL	7.3427 mL	18.3567 mL
	15 mM	0.4895 mL	2.4476 mL	4.8951 mL	12.2378 mL
	20 mM	0.3671 mL	1.8357 mL	3.6713 mL	9.1784 mL
	25 mM	0.2937 mL	1.4685 mL	2.9371 mL	7.3427 mL
	30 mM	0.2448 mL	1.2238 mL	2.4476 mL	6.1189 mL
	40 mM	0.1836 mL	0.9178 mL	1.8357 mL	4.5892 mL
	50 mM	0.1469 mL	0.7343 mL	1.4685 mL	3.6713 mL
	60 mM	0.1224 mL	0.6119 mL	1.2238 mL	3.0595 mL
	80 mM	0.0918 mL	0.4589 mL	0.9178 mL	2.2946 mL
	100 mM	0.0734 mL	0.3671 mL	0.7343 mL	1.8357 mL

Keywords

Ligustrazine

11 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Ligustrazine

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Anti-Cardiovascular Disease Compound Library

NMPA-Approved Drug Library

Medicine Food Homology Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Structurally Diverse Fragment Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Chinese Baijiu Compound Library

Flavors and Fragrances Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Drug Fragment Library

MedChemExpress（MCE）の使用を引用している文献 Ligustrazine

生物活性

化学情報

Publications (11)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Ligustrazine 関連分類

HY-N0264 関連分類